Gapping up
In reaction to strong earnings/guidance:
- REVG +18.9%, AAN +7.5%, DK +7%, THO +4.2%
Other news:
- MESA +21.3% (reported Mesa Airlines' operating performance for May)
- CLDX +13.6% (reports Phase 1 CDX-0159 data)
- CASI +11.6% (submits Clinical Trial Application (CTA) (IND) with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for CID-103)
- SRPT +9.5% (will present new data from the ongoing study of SRP-9003 on Monday)
- BCRX +6.2% (provides 48-week data showing treatment with Berotralstat provides robust and durable reductions in HAE Attacks)
- GILD +4.1% (Gilead Sciences and Galapagos NV (GLPG) announce new analyses from trials evaluating filgotinib in adults with psoriatic arthritis)
- JD +2.1% (launches Hong Kong Initial Public Offering )
- RDHL +1.9% (to provide update on development program with opaganib for COVID-19 and Phase 3 development program with RHB-204 for pulmonary nontuberculous mycobacteria infections)
- QFIN +1.7% (acquires 30% stake in Kincheng Bank of Tianjin)
- BLDP +1.7% (files for $750 mln mixed securities shelf offering)
- TSLA +1.6% (sold 11.905 Model 3 vehicles in China in May, which was triple April's volumes, according to Reuters)
- TEVA +1.4% (favorable NARCAN decision)
Analyst comments:
- MIK +21.6% (upgraded to Overweight from Neutral at JP Morgan and added to Analyst Focus List)
- PK +11.2% (upgraded to Outperform from Mkt Perform at Raymond James)
- JBLU +9.2% (upgraded to Neutral from Underperform at BofA/Merrill)
- BA +8.8% (initiated with a Buy at Seaport Global Securities)
- ALK +8.1% (upgraded to Buy from Neutral at BofA/Merrill)
- LLNW +6.2% (upgraded to Outperform from Mkt Perform at Raymond James)
- MGTA +6.1% (upgraded to Buy from Neutral at Goldman)
- DNKN +3.8% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- Z +3.7% (upgraded to Buy at Needham)
- RESI +3.3% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)
- NXPI +2.4% (upgraded to Outperform from In-line at Evercore ISI)
- AYI +1.7% (upgraded to Outperform from Perform at Oppenheimer)
- MAA +1.3% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- BKU +1.2% (upgraded to Buy from Neutral at BofA/Merrill)